echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > American Journal of Clinical Nutrition: Probiotic treatment fails to increase stool sIgA concentration

    American Journal of Clinical Nutrition: Probiotic treatment fails to increase stool sIgA concentration

    • Last Update: 2021-07-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Immune secretory immunoglobulin A (IgA) antibodies are anti-human and animal models of intestinal infection in one of the main defense mechanism
    .
    IgA provides protection by binding to microbial antigens, toxins and food proteins, and inhibits the adhesion and penetration of the intestinal epithelium


    .


    Immune secretory immunoglobulin A (IgA) antibodies are anti-human and animal models of intestinal infection in one of the main defense mechanism


    The use of probiotics is rapidly increasing, despite the questionable evidence of effectiveness, especially when it is associated with acute gastroenteritis (AGE) in children


    In 2017 , Stephen B Freedman's team completed the outpatient gastroenteritis treatment probiotic program (PROGUT) clinical trial, which randomly selected older children to receive a Lactobacillus rhamnosus/Lactobacillus helveticus probiotic mixture or the same placebo.


    The team recently published a research article in The American Journal of Clinical Nutrition to determine whether the fecal secretory immunoglobulin A (sIgA) concentration of children taking Lactobacillus rhamnosus/Lactobacillus helveticus probiotics varies with age compared with placebo Increase and increase .


    The study uses a multi-center, randomized, double-blind, placebo-controlled auxiliary study, with children receiving 5-day probiotics or placebo treatment as the study subjects


    .


    The study uses a multi-center, randomized, double-blind, placebo-controlled auxiliary study, with children receiving 5-day probiotics or placebo treatment as the study subjects


    Of the 886 PROGUT participants (15.
    0%), a total of 133 (n=66 probiotics, 67 placebos) provided all 3 specimens


    .


    Of the 886 PROGUT participants (15.


    There was no difference in fecal median sIgA concentration between the probiotic group and the placebo group at any study time point: median IQR on day 0: 1999 (768, 4071) and 2198 (702, 5278) (P=0.


    Fecal sIgA concentrations in the probiotic (A) (n = 66) and placebo (B) (n = 67) treatment groups at baseline and 5 and 28 days after randomization treatment


    .


    Fecal sIgA concentrations in the probiotic (A) (n = 66) and placebo (B) (n = 67) treatment groups at baseline and 5 and 28 days after randomization treatment


    Fecal sIgA concentrations of norovirus (A) and rotavirus (B) infected children at baseline and 5 and 28 days after randomized treatment
    .

    Fecal sIgA concentrations of norovirus (A) and rotavirus (B) infected children at baseline and 5 and 28 days after randomized treatment
    .

    Although the sIgA in the stool of the two groups decreased from day 5 to day 28 (P<0.
    001), the median change in sIgA concentration between the probiotic group and the placebo group was compared from day 0 to day 28.
    The 5-day median (IQR) [500(-1135,2362) and 362(-1122,4256); P=0.
    77, Cohen d=0.
    075] and the 5th to the 28th day [-1035(-3130,499) ) And -1260 (-4437, 843); P=0.
    70, Cohen d=0.
    067] there is no difference
    .

    Although the sIgA in the stool of the two groups decreased from day 5 to day 28 (P<0.
    001), the median change in sIgA concentration between the probiotic group and the placebo group was compared from day 0 to day 28.
    The 5-day median (IQR) [500(-1135,2362) and 362(-1122,4256); P=0.
    77, Cohen d=0.
    075] and the 5th to the 28th day [-1035(-3130,499) ) And -1260 (-4437, 843); P=0.
    70, Cohen d=0.
    067] there is no difference
    .

    This study quantified the effect of rhamnose/Swiss grass administration on sIgA concentration in feces of preschool children
    .
    Neither the rhamnose/Swiss grass group nor the placebo treatment group had a significant increase in sIgA concentration in stool within 5 days after the ED visit
    .
    After repeated measures and test sites were controlled, treatment had no effect on stool sIgA concentration
    .
    Although the stool sIgA concentration decreased significantly between the 5th day and the 28th day, this has nothing to do with the treatment allocation
    .
    In addition, it was found that there was no relationship between the severity of the disease and the concentration of sIgA in the stool
    .

    This study quantified the effect of rhamnose/Swiss grass administration on sIgA concentration in feces of preschool children
    .
    Neither the rhamnose/Swiss grass group nor the placebo treatment group had a significant increase in sIgA concentration in stool within 5 days after the ED visit
    .
    After repeated measures and test sites were controlled, treatment had no effect on stool sIgA concentration
    .
    Although the stool sIgA concentration decreased significantly between the 5th day and the 28th day, this has nothing to do with the treatment allocation
    .
    In addition, it was found that there was no relationship between the severity of the disease and the concentration of sIgA in the stool
    .

    In conclusion, in children with acute gastroenteritis in the emergency department, the rhamnose/swiss grass treatment did not increase the fecal sIgA concentration compared with placebo
    .

    In conclusion, in children with acute gastroenteritis in the emergency department, the rhamnose/swiss grass treatment did not increase the fecal sIgA concentration compared with placebo
    .
    In children with acute gastroenteritis attending the emergency department, rhamnose/Swiss grass treatment did not increase stool sIgA concentration compared with placebo
    .

    Original source

    Probiotic stool secretory immunoglobulin A modulation in children with gastroenteritis: a randomized clinical trial.
    The American Journal of Clinical Nutrition, Volume 113, Issue 4, April 2021, Pages 905–914, https://doi.
    org/10.
    1093/ajcn/nqaa369

    https://doi.
    org/10.
    1093/ajcn/nqaa369

     

    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.